Welcome to our dedicated page for Becton Dickinson & Co SEC filings (Ticker: BDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Becton, Dickinson and Company filings document the reporting, governance and capital-structure matters of a New York Stock Exchange-listed medical technology issuer. Its Form 8-K disclosures cover quarterly operating results, non-GAAP financial measures, dividend and capital allocation updates, executive appointments, compensatory arrangements and amendments to corporate by-laws.
The filing record also documents BD's completed separation of its Biosciences and Diagnostic Solutions business and related recast historical financial information presenting that business as discontinued operations. Capital-structure disclosures include registered common stock, NYSE-listed notes and tender-offer activity involving senior notes and debentures.
Becton Dickinson & Co ownership filing: Vanguard Portfolio Management reports beneficial ownership of 15,388,359 shares of Common Stock, representing 5.4% of the class as of 03/31/2026. The filing shows sole voting power for 71,117 shares and sole dispositive power for 15,388,359 shares. The filing is signed on 04/29/2026 by Ashley Grim.
Becton Dickinson & Co executive Michael Feld, EVP and Chief Revenue Officer, reported an open-market sale of 74 shares of Common Stock at $151.94 per share. After this transaction, he directly holds 21,159 shares of Becton Dickinson common stock, according to the filing.
Becton, Dickinson and Company notice of proposed sale of common stock under Rule 144/Section 5, identifying restricted stock units and prior 10b5-1 sales by Michael Feld. The filing lists 74 Restricted Stock Units with an 08/20/2025 date and two reported 10b5-1 sales of 75 shares on 02/26/2026 and 03/26/2026.
Becton, Dickinson and Company announced that Richard (Rick) Byrd, executive vice president and president of the Interventional segment, has informed the company of his intention to retire after nearly 25 years with BD. He has led the Interventional segment since September 2022 and previously held several other leadership roles.
Byrd will remain in his current position through June, providing time for an orderly transition, and BD intends to name a successor before his retirement date. The company also issued a press release describing his contributions across multiple segments and his role during the COVID-19 pandemic.
Becton, Dickinson and Company announced that Richard (Rick) Byrd, executive vice president and president of the Interventional segment, has informed the company of his intention to retire after nearly 25 years with BD. He has led the Interventional segment since September 2022 and previously held several other leadership roles.
Byrd will remain in his current position through June, providing time for an orderly transition, and BD intends to name a successor before his retirement date. The company also issued a press release describing his contributions across multiple segments and his role during the COVID-19 pandemic.
Becton, Dickinson and Company announced that Richard (Rick) Byrd, executive vice president and president of the Interventional segment, has informed the company of his intention to retire after nearly 25 years with BD. He has led the Interventional segment since September 2022 and previously held several other leadership roles.
Byrd will remain in his current position through June, providing time for an orderly transition, and BD intends to name a successor before his retirement date. The company also issued a press release describing his contributions across multiple segments and his role during the COVID-19 pandemic.
Becton Dickinson & Co executive Neal Shana Carol reported a tax-related share withholding tied to equity compensation. On this Form 4, 1,146 shares of common stock were withheld to cover withholding taxes upon vesting of previously granted restricted stock units. After this non-market disposition, Carol directly holds 23,966 common shares. The filing also notes that direct holdings reflect adjustments connected to the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp., which affected the number of shares underlying previously reported unvested time-based restricted stock units.
Becton, Dickinson and Company has recast its historical financial statements to reflect the February 9, 2026 spin-off and combination of its Biosciences and Diagnostic Solutions business with Waters Corporation. The recast data present BD as a standalone company, treating that business as discontinued operations.
For the twelve months ended September 30, 2025, BD reported revenues of $18,544 million and net income from continuing operations of $1,100 million, with diluted earnings per share from continuing operations of $3.81, compared with $16,820 million, $1,054 million and $3.62 in 2024. BD also provides non-GAAP measures that adjust for purchase accounting, integration and restructuring costs, separation-related items, certain regulatory and legal costs, and related tax effects to highlight underlying operating performance.
Becton Dickinson & Co executive Michael Feld, EVP and Chief Revenue Officer, sold 75 shares of common stock at $156.83 per share in an open-market transaction executed under a Rule 10b5-1 trading plan. After this planned sale, he directly owns 21,233 shares.
Michael Feld reports proposed and completed sales of Common Stock. The filing lists a proposed sale of 75 Restricted Stock Units to be sold through the issuer on 08/20/2025. It also records two 10b5-1 sales by Michael Feld of 75 shares each on 02/26/2026 and 01/26/2026 with amounts shown as 13638.00 and 15204.75, respectively.
The broker listed is Morgan Stanley Smith Barney LLC at New York Plaza. The filing is a routine notice of sale under Form 144 and documents the seller, security type, sale dates, and per-sale amounts as provided.
Becton Dickinson & Co Schedule 13G/A (Amendment No. 14) reports that The Vanguard Group disaggregated certain subsidiaries following an internal realignment and now reports 0 shares beneficially owned of the company's common stock, representing 0% of the class. The amendment explains the change is in accordance with SEC Release No. 34-39538 and reflects separate reporting by subsidiaries effective after the internal reorganization.
Becton Dickinson & Co executive Lanesha Minnix received an equity award of 7,492 shares of Common Stock on March 16, 2026. The Form 4 classifies this as a grant or award acquisition at no purchase price. A footnote explains the award represents restricted stock units granted under the company’s 2004 equity-based compensation plan. Following this grant, Minnix directly holds 7,492 shares.